Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Disc Medicine Q3 2026 Results: Net Loss of $59.5M, Loss Narrows

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on hematologic diseases, reporting as a large accelerated filer with 45,540,842 shares of common stock outstanding as of October 29, 2026. The company continues to incur significant net losses, has no products approved for commercial sale, and anticipates the need for substantial additional funding to support its clinical development programs, including bitopertin.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-59.4-62.2
Net income-59.5-62.3
EPS (diluted, $ a share)$-1.53$-1.77

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: IRON. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Disc Medicine, Inc.: key numbers

Share price
$76.59Close, Nov 16
Market cap
$3.49B
Shares outstanding
45.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Disc Medicine, Inc.

All →
5:21 PM ET Form 4
Insider Selling

Disc Medicine CMO William Jacob Savage Sells $1.36M of Stock

William Jacob Savage, CMO, sold 16,035 shares of Disc Medicine, Inc. at $85.09 a share, worth $1.36M in total on Nov 10, 2026. Shares held after the trade: 63,445 (-20.2%).

Value
$1.36M
Shares
16,035
Price
$85.09
Role
CMO
Holding change
-20.2%
Trade date
Nov 10, 2026
8:38 AM ET 8-K
Financial Results

Disc Medicine Financial Results

Disc Medicine reported Q3 2026 financial results and provided a corporate update, highlighting the successful Phase 3 APOLLO trial of bitopertin which met all primary and secondary endpoints. The company plans to resubmit its NDA for bitopertin by year-end 2026 and recently strengthened its balance sheet with a $486 million public offering in October, extending its cash runway into 2030.

“In our first pivotal trial readout as a company, APOLLO delivered strong and compelling evidence of the potential clinical benefit of bitopertin for patients with EPP. We look forward to engaging with regulators with the goal of bringing an important, innovative medicine to this community as efficiently as possible.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

“Alongside our anticipated end-of-Phase 2 FDA meeting for selcodebart in anemia of myelofibrosis in the fourth quarter and a strengthened balance sheet, we are well positioned to support the anticipated launch of bitopertin and advance two additional programs toward pivotal-stage development in 2027.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer
5:12 PM ET 8-K
Capital Raise

Disc Medicine Capital Raise of $450M

Disc Medicine closed an underwritten public offering of 6,000,000 shares of common stock at a price of $75.00 per share, generating gross proceeds of $450 million. The company expects the net proceeds to extend its cash runway into 2030, supporting the clinical development and potential commercialization of its hematologic disease treatments, including bitopertin.

Value
$450M
5:33 PM ET Form 4
Insider Selling

Disc Medicine Director Kevin Bitterman Sells $3.34M of Stock

Kevin Bitterman, Director, sold 41,655 shares of Disc Medicine, Inc. at $79.95 to $80.23 a share (average $80.13) in 7 transactions, worth $3.34M in total between Oct 19, 2026 and Oct 21, 2026. Shares held after the trade: 12,991 (-2.0%).

Value
$3.34M
Shares
41,655
Average price
$80.13
Role
Director
Holding change
-2.0%
Trade date
Oct 19, 2026 to Oct 21, 2026
7:08 AM ET 8-K
Clinical Trial Data

Disc Medicine Clinical Trial Data

Disc Medicine announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, including a 41.4% reduction in whole-blood PPIX and a significant increase in pain-free light tolerance, with an NDA resubmission planned by the end of 2026.

Term
6 months

“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”

Will Savage, M.D., Ph.D., Chief Medical Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.